{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:37:14Z","timestamp":1764225434901,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T00:00:00Z","timestamp":1533686400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00277-018-3468-5","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T04:30:07Z","timestamp":1533702607000},"page":"2391-2401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma"],"prefix":"10.1007","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8382-0140","authenticated-orcid":false,"given":"Jonathan","family":"Farhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamel","family":"Laribi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corentin","family":"Orvain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lien","family":"Sutra Del Galy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Clavert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Rousselet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Tanguy-Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Hunault-Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Pierre","family":"Moles-Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,8]]},"reference":[{"key":"3468_CR1","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","volume":"16","author":"K Hoang-Xuan","year":"2015","unstructured":"Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rud\u00e0 R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CMF, Ferreri AJM, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M (2015) Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 16:e322\u2013e332","journal-title":"Lancet Oncol"},{"key":"3468_CR2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ajh.23551","volume":"88","author":"BP O\u2019Neill","year":"2013","unstructured":"O\u2019Neill BP, Decker PA, Tieu C, Cerhan JR (2013) The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin\u2019s lymphoma. Am J Hematol 88:997\u20131000. \n                    https:\/\/doi.org\/10.1002\/ajh.23551","journal-title":"Am J Hematol"},{"key":"3468_CR3","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/leu.2011.169","volume":"25","author":"M Deckert","year":"2011","unstructured":"Deckert M, Engert A, Br\u00fcck W, Ferreri AJM, Finke J, Illerhaus G, Klapper W, Korfel A, K\u00fcppers R, Maarouf M, Montesinos-Rongen M, Paulus W, Schlegel U, Lassmann H, Wiestler OD, Siebert R, DeAngelis LM (2011) Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia 25:1797\u20131807. \n                    https:\/\/doi.org\/10.1038\/leu.2011.169","journal-title":"Leukemia"},{"key":"3468_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","volume":"107","author":"S Camilleri-Bro\u00ebt","year":"2006","unstructured":"Camilleri-Bro\u00ebt S, Crini\u00e8re E, Bro\u00ebt P et al (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107:190\u2013196. \n                    https:\/\/doi.org\/10.1182\/blood-2005-03-1024","journal-title":"Blood"},{"key":"3468_CR5","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","volume":"26","author":"B Kasenda","year":"2015","unstructured":"Kasenda B, Ferreri AJM, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay JY, Hoang-Xuan K, Pulczynski EJ, Foss\u00e5 A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill BP, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor TT, Illerhaus G, Briel M (2015) First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol 26:1305\u20131313. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv076","journal-title":"Ann Oncol"},{"key":"3468_CR6","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/WCO.0000000000000145","volume":"27","author":"P Roth","year":"2014","unstructured":"Roth P, Hoang-Xuan K (2014) Challenges in the treatment of elderly patients with primary central nervous system lymphoma. Curr Opin Neurol 27:697\u2013701. \n                    https:\/\/doi.org\/10.1097\/WCO.0000000000000145","journal-title":"Curr Opin Neurol"},{"key":"3468_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","volume":"21","author":"AJM Ferreri","year":"2003","unstructured":"Ferreri AJM, Blay J-Y, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell\u2019Oro S, Zucca E, Cavalli F (2003) Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol 21:266\u2013272","journal-title":"J Clin Oncol"},{"key":"3468_CR8","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","volume":"24","author":"LE Abrey","year":"2006","unstructured":"Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711\u20135715. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.08.2941","journal-title":"J Clin Oncol"},{"key":"3468_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"3468_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0165-1781(92)90005-N","volume":"41","author":"MD Miller","year":"1992","unstructured":"Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF III (1992) Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41:237\u2013248","journal-title":"Psychiatry Res"},{"key":"3468_CR11","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","volume":"56","author":"F Salvi","year":"2008","unstructured":"Salvi F, Miller MD, Grilli A, Giorgi R, Towers AL, Morichi V, Spazzafumo L, Mancinelli L, Espinosa E, Rappelli A, Dess\u00c3-Fulgheri P (2008) A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 56:1926\u20131931. \n                    https:\/\/doi.org\/10.1111\/j.1532-5415.2008.01935.x","journal-title":"J Am Geriatr Soc"},{"key":"3468_CR12","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","volume":"23","author":"CA Bellera","year":"2012","unstructured":"Bellera CA, Rainfray M, Mathoulin-P\u00e9lissier S et al (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23:2166\u20132172. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdr587","journal-title":"Ann Oncol"},{"key":"3468_CR13","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.1990.8.12.1935","volume":"8","author":"WM Hryniuk","year":"1990","unstructured":"Hryniuk WM, Goodyear M (1990) The calculation of received dose intensity. J Clin Oncol 8:1935\u20131937","journal-title":"J Clin Oncol"},{"key":"3468_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s002770050330","volume":"75","author":"MA Fridrik","year":"1997","unstructured":"Fridrik MA, Greil R, Hausmaninger H et al (1997) Randomized open label phase III trial of CEOP\/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP\/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin\u2019s lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy. Ann Hematol 75:135\u2013140","journal-title":"Ann Hematol"},{"key":"3468_CR15","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034\u20135043. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.13.524","journal-title":"J Clin Oncol"},{"key":"3468_CR16","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010)"},{"key":"3468_CR17","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","volume":"24","author":"IT Gavrilovic","year":"2006","unstructured":"Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570\u20134574. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.06.6910","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"3468_CR18","first-page":"40","volume":"10","author":"B Desablens","year":"1999","unstructured":"Desablens B, Gardembas M, Delwail V et al (1999) Primary CNS lymphomas: long term results of the GOELAMS LCP88 trial with a focus on neurological complications among 152 patients. Ann Oncol 10(Suppl 3):40 (abstract)","journal-title":"Ann Oncol"},{"key":"3468_CR19","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","volume":"21","author":"PMP Poortmans","year":"2003","unstructured":"Poortmans PMP, Kluin-Nelemans HC, Haaxma-Reiche H, van\u2019t Veer M, Hansen M, Soubeyran P, Taphoorn M, Thomas J, van den Bent M, Fickers M, van Imhoff G, Rozewicz C, Teodorovic I, van Glabbeke M (2003) High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21:4483\u20134488. \n                    https:\/\/doi.org\/10.1200\/JCO.2003.03.108","journal-title":"J Clin Oncol"},{"key":"3468_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10428194.2015.1045894","volume":"57","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Crawford J, Tomita D, Whittaker S, Dale DC (2015) Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma 57:1\u20138. \n                    https:\/\/doi.org\/10.3109\/10428194.2015.1045894","journal-title":"Leuk Lymphoma"},{"key":"3468_CR21","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/ajh.23812","volume":"89","author":"G Olivier","year":"2014","unstructured":"Olivier G, Clavert A, Lacotte-Thierry L, Gardembas M, Escoffre-Barbe M, Brion A, Cumin I, Legouffe E, Solal-Celigny P, Chabin M, Ingrand P, Colombat P, Delwail V (2014) A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial. Am J Hematol 89:1024\u20131029. \n                    https:\/\/doi.org\/10.1002\/ajh.23812","journal-title":"Am J Hematol"},{"key":"3468_CR22","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","volume":"2","author":"A Omuro","year":"2015","unstructured":"Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Touitou V, Barri\u00e9 M, del Rio MS, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy ML, Hoang-Xuan K (2015) Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol 2:e251\u2013e259","journal-title":"Lancet Haematol"},{"key":"3468_CR23","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/leu.2016.334","volume":"31","author":"K Fritsch","year":"2017","unstructured":"Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, M\u00f6hle R, L\u00f6w S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, He\u00df G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, R\u00f6th A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G (2017) High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia 31:846\u2013852. \n                    https:\/\/doi.org\/10.1038\/leu.2016.334","journal-title":"Leukemia"},{"key":"3468_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","volume":"77","author":"H Wildiers","year":"2011","unstructured":"Wildiers H, Reiser M (2011) Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 77:221\u2013240. \n                    https:\/\/doi.org\/10.1016\/j.critrevonc.2010.02.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"3468_CR25","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.3109\/10428194.2012.676177","volume":"53","author":"M Joerger","year":"2012","unstructured":"Joerger M, Huitema ADR, Illerhaus G, Ferreri AJM (2012) Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma. Leuk Lymphoma 53:1867\u20131875. \n                    https:\/\/doi.org\/10.3109\/10428194.2012.676177","journal-title":"Leuk Lymphoma"},{"key":"3468_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","volume":"90","author":"AJM Ferreri","year":"2004","unstructured":"Ferreri AJM, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, Gubkin A, Calderoni A, Spina M, Brandes A, Ferrarese F, Rognone A, Govi S, Dell'Oro S, Locatelli M, Villa E, Reni M (2004) Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 90:353\u2013358. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6601472","journal-title":"Br J Cancer"},{"key":"3468_CR27","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","volume":"374","author":"AJM Ferreri","year":"2009","unstructured":"Ferreri AJM, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512\u20131520. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(09)61416-1","journal-title":"Lancet"},{"key":"3468_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242. \n                    https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"key":"3468_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jocn.2014.02.002","volume":"21","author":"T Siegal","year":"2014","unstructured":"Siegal T (2014) Primary central nervous system lymphoma: current state of anti-CD20 therapy and appraisal of reported response criteria. J Clin Neurosci 21:709\u2013715. \n                    https:\/\/doi.org\/10.1016\/j.jocn.2014.02.002","journal-title":"J Clin Neurosci"},{"key":"3468_CR30","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","volume":"25","author":"GD Shah","year":"2007","unstructured":"Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25:4730\u20134735. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.12.5062","journal-title":"J Clin Oncol"},{"key":"3468_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11060-012-0891-7","volume":"109","author":"T Birnbaum","year":"2012","unstructured":"Birnbaum T, Stadler EA, von Baumgarten L, Straube A (2012) Rituximab significantly improves complete response rate in patients with primary CNS lymphoma. J Neuro-Oncol 109:285\u2013291. \n                    https:\/\/doi.org\/10.1007\/s11060-012-0891-7","journal-title":"J Neuro-Oncol"},{"key":"3468_CR32","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/neuonc\/not032","volume":"15","author":"G Gregory","year":"2013","unstructured":"Gregory G, Arumugaswamy A, Leung T, Chan KL, Abikhair M, Tam C, Bajel A, Cher L, Grigg A, Ritchie D, Opat S (2013) Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro-Oncology 15:1068\u20131073. \n                    https:\/\/doi.org\/10.1093\/neuonc\/not032","journal-title":"Neuro-Oncology"},{"key":"3468_CR33","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/ajh.24204","volume":"90","author":"R Kansara","year":"2015","unstructured":"Kansara R, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D (2015) Rituximab with high-dose methotrexate in primary central nervous system lymphoma. Am J Hematol 90:1149\u20131154. \n                    https:\/\/doi.org\/10.1002\/ajh.24204","journal-title":"Am J Hematol"},{"key":"3468_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1212\/WNL.0000000000000593","volume":"83","author":"M Holdhoff","year":"2014","unstructured":"Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X (2014) High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology 83:235\u2013239","journal-title":"Neurology"},{"key":"3468_CR35","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00277-015-2470-4","volume":"94","author":"M Madle","year":"2015","unstructured":"Madle M, Kr\u00e4mer I, Lehners N, Schwarzbich M, Wuchter P, Herfarth K, Egerer G, Ho AD, Witzens-Harig M (2015) The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma. Ann Hematol 94:1853\u20131857. \n                    https:\/\/doi.org\/10.1007\/s00277-015-2470-4","journal-title":"Ann Hematol"},{"key":"3468_CR36","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/neuonc\/noq011","volume":"12","author":"MC Chamberlain","year":"2010","unstructured":"Chamberlain MC, Johnston SK (2010) High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro-Oncology 12:736\u2013744. \n                    https:\/\/doi.org\/10.1093\/neuonc\/noq011","journal-title":"Neuro-Oncology"},{"key":"3468_CR37","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/annonc\/mdq712","volume":"22","author":"K Fritsch","year":"2011","unstructured":"Fritsch K, Kasenda B, Hader C, Nikkhah G, Prinz M, Haug V, Haug S, Ihorst G, Finke J, Illerhaus G (2011) Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol 22:2080\u20132085. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdq712","journal-title":"Ann Oncol"},{"key":"3468_CR38","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","volume":"31","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD (2013) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 31:3061\u20133068. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.46.9957","journal-title":"J Clin Oncol"},{"key":"3468_CR39","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJM Ferreri","year":"2016","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Ros\u00e9e PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rud\u00e0 R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, G\u00f8rl\u00f8v JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217\u2013e227. \n                    https:\/\/doi.org\/10.1016\/S2352-3026(16)00036-3","journal-title":"Lancet Haematol"},{"key":"3468_CR40","first-page":"582","volume":"130","author":"J Bromberg","year":"2017","unstructured":"Bromberg J, Issa S, Bukanina K et al (2017) Effect of rituximab in primary central nervous system lymphoma - results of the Randomized Phase III HOVON 105\/ALLG NHL 24 Study. Blood 130:582\u2013582","journal-title":"Blood"},{"key":"3468_CR41","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s12185-017-2316-z","volume":"106","author":"Y Song","year":"2017","unstructured":"Song Y, Wen Y, Xue W, Zhang Y, Zhang M (2017) Effect of rituximab on primary central nervous system lymphoma: a meta-analysis. Int J Hematol 106:612\u2013621. \n                    https:\/\/doi.org\/10.1007\/s12185-017-2316-z","journal-title":"Int J Hematol"},{"key":"3468_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1586\/17474086.2015.1024650","volume":"8","author":"C Terret","year":"2015","unstructured":"Terret C, Albrand G, Rainfray M, Soubeyran P (2015) Impact of comorbidities on the treatment of non-Hodgkin\u2019s lymphoma: a systematic review. Expert Rev Hematol 8:329\u2013341. \n                    https:\/\/doi.org\/10.1586\/17474086.2015.1024650","journal-title":"Expert Rev Hematol"},{"key":"3468_CR43","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1002\/cncr.26646","volume":"118","author":"M Extermann","year":"2012","unstructured":"Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ III, Balducci L (2012) Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118:3377\u20133386. \n                    https:\/\/doi.org\/10.1002\/cncr.26646","journal-title":"Cancer"},{"key":"3468_CR44","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","volume":"29","author":"A Hurria","year":"2011","unstructured":"Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29:3457\u20133465. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.34.7625","journal-title":"J Clin Oncol"},{"key":"3468_CR45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.critrevonc.2010.05.009","volume":"79","author":"AA Aaldriks","year":"2011","unstructured":"Aaldriks AA, Maartense E, le Cessie S, Giltay EJ, Verlaan HACM, van der Geest LGM, Kloosterman-Boele WM, Peters-Dijkshoorn MT, Blansjaar BA, van Schaick HW, Nortier JWR (2011) Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol 79:205\u2013212. \n                    https:\/\/doi.org\/10.1016\/j.critrevonc.2010.05.009","journal-title":"Crit Rev Oncol Hematol"},{"key":"3468_CR46","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1200\/JCO.2010.32.0796","volume":"29","author":"R Kanesvaran","year":"2011","unstructured":"Kanesvaran R, Li H, Koo K-N, Poon D (2011) Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer. J Clin Oncol 29:3620\u20133627. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.32.0796","journal-title":"J Clin Oncol"},{"key":"3468_CR47","doi-asserted-by":"publisher","first-page":"e115060","DOI":"10.1371\/journal.pone.0115060","volume":"9","author":"P Soubeyran","year":"2014","unstructured":"Soubeyran P, Bellera C, Goyard J, Heitz D, Cur\u00e9 H, Rousselot H, Albrand G, Servent V, Jean OS, van Praagh I, Kurtz JE, P\u00e9rin S, Verhaeghe JL, Terret C, Desauw C, Girre V, Mertens C, Mathoulin-P\u00e9lissier S, Rainfray M (2014) Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. PLoS One 9:e115060. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0115060","journal-title":"PLoS One"},{"key":"3468_CR48","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/annonc\/mdu210","volume":"26","author":"L Decoster","year":"2015","unstructured":"Decoster L, Van Puyvelde K, Mohile S et al (2015) Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations\u2020. Ann Oncol 26:288\u2013300. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdu210","journal-title":"Ann Oncol"},{"key":"3468_CR49","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jgo.2015.07.006","volume":"6","author":"S Dubruille","year":"2015","unstructured":"Dubruille S, Libert Y, Roos M, Vandenbossche S, Collard A, Meuleman N, Maerevoet M, Etienne AM, Reynaert C, Razavi D, Bron D (2015) Identification of clinical parameters predictive of one-year survival using two geriatric tools in clinically fit older patients with hematological malignancies: major impact of cognition. J Geriatr Oncol 6:362\u2013369. \n                    https:\/\/doi.org\/10.1016\/j.jgo.2015.07.006","journal-title":"J Geriatr Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3468-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3468-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3468-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T19:19:08Z","timestamp":1565205548000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3468-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,8]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3468"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3468-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2018,8,8]]},"assertion":[{"value":"27 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}